Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations

Maria Pagano, Nuria Maria Asensio Sierra, Michele Panebianco, Giulio Rossi, Roberta Gnoni, Giancarlo Bisagni, Corrado Boni

Research output: Contribution to journalArticle

Abstract

Purpose: To retrospectively evaluate sorafenib activity and safety in patients with metastatic thymic carcinoma (TC) and to correlate outcome with c-KIT and PDGFR-alpha mutational status. Patients and Methods: Patients with metastatic thymic carcinoma treated with sorafenib after at least one prior line of chemotherapy were included. Objective response rate (ORR) and toxicity were evaluated. Analysis of c-KIT and PDGFR-alpha mutational status was performed retrospectively. Results: From October 2007 to August 2011, 5 patients with metastatic thymic carcinoma were evaluated. A median of 8 cycles of sorafenib (range=3-29) were administered. Two patients (40%) displayed a partial response (PR), two patients presented stable disease (SD), while one patient had progression. The median progression-free (PFS) and overall survival were 28 weeks and 92 weeks, respectively. At mutational analysis, only one patient with PR had c-KIT mutation in exon 17 and was successfully treated with sunitinib for 12 months after progression to sorafenib. No PDGFR-alpha mutations were found. Conclusion: Sorafenib activity seems independent from the c-KIT and PDGFR-alpha mutational status. After progression, sequence treatment with a different tyrosine kinase inhibitor can be considered. These results are promising and need further confirmation on larger, possibly prospective, series of patients.

Original languageEnglish
Pages (from-to)5105-5110
Number of pages6
JournalAnticancer Research
Volume34
Issue number9
Publication statusPublished - Sep 1 2014

Keywords

  • c-KIT
  • PDGFR alpha
  • Sorafenib
  • Thymic carcinoma
  • Tyrosine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations'. Together they form a unique fingerprint.

  • Cite this

    Pagano, M., Sierra, N. M. A., Panebianco, M., Rossi, G., Gnoni, R., Bisagni, G., & Boni, C. (2014). Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Anticancer Research, 34(9), 5105-5110.